Wegovy: Weight Loss Dosing and Tracking

Quick Reference

• What it is: Semaglutide, a GLP-1 receptor agonist
• What it treats: Chronic weight management in adults with obesity or overweight with comorbidities (FDA-approved); cardiovascular risk reduction in overweight/obese adults
• How it's administered: Once-weekly subcutaneous injection via pre-filled pen
• Standard dosing range: 0.25 mg (initiation) to 2.4 mg (maintenance)
• Needle: 34-gauge, 4 mm (built into pen)

Wegovy is semaglutide prescribed specifically for chronic weight management. FDA-approved in June 2021, it's the same molecule as Ozempic but dosed higher (2.4 mg vs. 2 mg maximum) with a longer titration schedule tailored to the weight loss indication. If you've been prescribed Wegovy or are considering it, this page covers dosing, injection technique, side effects, what to monitor, and how to track your treatment.

What Wegovy Is

Wegovy is a brand-name semaglutide product manufactured by Novo Nordisk. It comes as a pre-filled, single-dose pen -- unlike Ozempic, which is multi-dose. Each Wegovy pen contains one injection at one specific dose. You use it once and discard it.

The pens are color-coded by dose level:

• 0.25 mg -- dark red cap
• 0.5 mg -- dark red cap
• 1.0 mg -- dark red cap
• 1.7 mg -- blue cap
• 2.4 mg -- blue cap

Each monthly prescription contains 4 pens (one per week). During titration, your dose changes monthly, so each month's box is a different strength.

Wegovy is not a short-term weight loss drug. The clinical evidence and FDA labeling position it as a long-term therapy. Stopping it typically results in weight regain, which is consistent with how the drug works -- it modifies appetite signaling, and when that signal is removed, appetite returns to baseline.

How It Works

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, which your gut naturally produces after meals. The synthetic version resists enzymatic breakdown, extending its half-life to approximately 7 days.

For weight management specifically, the key mechanisms are:

• Central appetite suppression: Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety signaling. This is what many patients describe as the reduction of "food noise" -- a persistent background preoccupation with eating that diminishes on treatment.
• Delayed gastric emptying: Food stays in the stomach longer, which extends the feeling of fullness after meals and reduces the urge to eat again quickly.
• Improved insulin sensitivity: While less directly related to weight loss, better insulin signaling reduces the metabolic dysfunction that often accompanies obesity.

The net effect is reduced caloric intake driven by genuine changes in appetite, not willpower. In STEP 1, semaglutide-treated participants consumed meaningfully fewer calories -- not because they were told to diet, but because they were less hungry.

For a detailed breakdown of the semaglutide mechanism across all formulations, see our semaglutide guide.

Approved Uses

Wegovy is FDA-approved for:

1. Chronic weight management in adults with a BMI of 30 or greater (obesity), or BMI of 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia).
2. Chronic weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex).
3. Cardiovascular risk reduction in adults with established cardiovascular disease who are overweight or obese (added to the label following the SELECT trial in 2024).

The cardiovascular indication was a significant addition. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults with established CVD -- independent of diabetes status. This shifted the clinical framing of Wegovy from "weight loss drug" to "cardiometabolic therapy."

Dosing

Wegovy's titration takes 16 weeks -- four weeks at each dose level before the next increase.

This schedule is slower than Ozempic's titration because the target dose is higher and the tolerability threshold matters more in a population that may not have prior experience with GLP-1 agonists.

If you can't tolerate a dose increase: Your prescriber may hold you at the current dose for an additional 4 weeks before retrying the escalation. If you can't tolerate 2.4 mg, 1.7 mg can be used as a maintenance dose, though the evidence base is strongest at the full 2.4 mg.

Dose timing: Same day each week, any time of day, with or without food. You can shift your injection day as long as at least 2 days (48 hours) have passed since your last dose.

Injection Sites and Technique

Wegovy is administered subcutaneously. The pen has a 34-gauge, 4 mm hidden needle -- you don't see the needle during injection, which reduces injection anxiety.

Approved sites

• Abdomen: Most common choice. Inject at least 2 inches from the navel. Avoid the beltline area.
• Front of the thigh: Mid-thigh, anterior surface. Reliable alternative.
• Back of the upper arm: Best if someone else is administering. Difficult to self-inject here with consistent technique.

Technique

1. Remove the pen from the refrigerator 30 minutes before use (room temperature injection is more comfortable).
2. Pull off the pen cap.
3. Place the pen flat against your skin at the injection site.
4. Press and hold the injection button. You'll hear a click when the injection starts and a second click when it's complete.
5. Hold for 5-10 seconds after the second click to ensure full delivery.
6. Remove and discard the pen in a sharps container.

No priming is needed. No dose dialing. Each pen is one dose.

Site rotation

Rotate sites weekly. A simple rotation that works well with the monthly dose changes: use abdomen for month 1, right thigh for month 2, left thigh for month 3, and abdomen again for month 4, rotating quadrants within each region. Once on maintenance, cycle through all three regions on a repeating schedule.

Detailed rotation systems are covered in our GLP-1 injection site rotation guide.

Side Effects to Track

Common (>5% in STEP trials)

• Nausea: Reported by ~44% on 2.4 mg vs. 18% on placebo in STEP 1. Most common during dose escalation. Typically improves within weeks at each dose level.
• Diarrhea: ~30% on drug vs. ~16% on placebo.
• Vomiting: ~24% on drug vs. ~6% on placebo. The titration schedule is designed to minimize this.
• Constipation: ~24% on drug. Can alternate with diarrhea. Adequate hydration and fiber help.
• Abdominal pain: ~20%.
• Headache: ~14%.
• Fatigue: ~11%.

Most GI side effects are rated mild to moderate and are concentrated in the first 1-3 days after each dose increase. The pattern is predictable: dose goes up, symptoms appear, symptoms fade over 2-3 weeks, next dose increase, repeat.

Less common but important

• Gallbladder events: Gallstones and cholecystitis occur at higher rates with rapid weight loss. STEP 1 reported cholelithiasis in 2.6% of semaglutide participants vs. 1.2% on placebo.
• Pancreatitis: Rare. Watch for severe, persistent abdominal pain radiating to the back.
• Hypoglycemia: Uncommon with Wegovy alone. Risk increases if combined with insulin or sulfonylureas.
• Suicidal ideation: The FDA has required monitoring for mood changes. Report any new or worsening depression or suicidal thoughts to your prescriber immediately.
• Injection site reactions: Occasional redness or irritation. Usually self-resolving.

Boxed warning

Same as all semaglutide products: thyroid C-cell tumors observed in rodent studies. Not confirmed in humans. Contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

What to Monitor

Bloodwork and clinical measures

• Weight: Weekly, same day, same conditions (morning, after voiding, before eating). This is the primary outcome measure.
• Waist circumference: Monthly. A better indicator of visceral fat loss than scale weight alone.
• Blood pressure: Monthly or per your prescriber's guidance. Weight loss often improves BP, which may require adjustment of antihypertensives.
• Lipid panel: Baseline and every 3-6 months. Triglycerides and LDL often improve.
• HbA1c / fasting glucose: Even if you don't have diabetes, tracking metabolic markers is valuable. Many Wegovy patients have prediabetes that improves on treatment.
• Kidney function (eGFR): Baseline and periodic, especially if you experience significant GI fluid losses.
• Liver enzymes: Baseline recommended. Metabolic-associated fatty liver disease often improves with weight loss.

Self-tracking

• Appetite and satiety: Subjective but useful. Rate your hunger daily on a 1-10 scale. This helps identify when the drug is working and can flag issues if appetite suddenly returns (possible injection error or absorption problem).
• GI symptoms: Log timing relative to injection, severity, and duration. Your prescriber needs this data to make titration decisions.
• Energy levels and mood: Weight loss and caloric deficit affect both. Track patterns, not just snapshots.
• Physical activity: Not because Wegovy requires exercise to work, but because the data shows that combining treatment with physical activity produces better body composition outcomes.

Comparison to Alternatives

Wegovy's distinguishing advantages are its cardiovascular outcome data (SELECT trial), its established safety profile with years of real-world use, and the once-weekly dosing schedule. Zepbound (tirzepatide) shows greater average weight loss in trials but lacks cardiovascular outcome data as of this writing. Saxenda requires daily injections, which reduces adherence. Contrave is oral but produces significantly less weight loss.

Tracking Your Treatment

The 16-week Wegovy titration is a process that demands tracking. You're changing doses monthly, potentially experiencing different side effects at each level, and trying to maintain a consistent injection schedule. Relying on memory for all of this is a recipe for missed doses and confused conversations with your prescriber.

What to log each week:

• Date and time of injection
• Dose level (critical during the 16-week titration)
• Pen lot number (from the box -- useful for recalls or quality issues)
• Injection site and side
• Side effects within 72 hours, with severity
• Weight (same-day measurement)
• Next scheduled injection date

Over months, this log becomes a powerful record. You can see exactly when side effects peaked, how your weight responded at each dose level, and whether patterns emerge that help guide treatment decisions.

Done Dose is designed to track exactly this. Set up your Wegovy titration schedule, get reminders on injection day, log your dose and site in seconds, and track side effects and weight in one place. When your prescriber asks how treatment is going, you have the data.

Frequently Asked Questions

How much weight can you lose on Wegovy?

In the STEP 1 trial, participants on Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Individual results vary significantly based on adherence, diet, exercise, and starting weight.

How long does it take to reach the full Wegovy dose?

The standard Wegovy titration takes 16 weeks. You start at 0.25 mg and escalate monthly through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg at week 17. Your prescriber may slow this schedule if you have significant side effects.

What happens when you stop taking Wegovy?

The STEP 4 trial showed that participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of the weight they had lost, while those who continued treatment lost additional weight. Wegovy is designed as a long-term therapy, not a short-term intervention.

Can you take Wegovy if you don't have diabetes?

Yes. Wegovy is specifically FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes. It is also approved for adolescents aged 12 and older with obesity.

Is Wegovy the same drug as Ozempic?

Both are semaglutide made by Novo Nordisk. Ozempic is approved for type 2 diabetes with a max dose of 2 mg. Wegovy is approved for chronic weight management with a max dose of 2.4 mg and a longer 16-week titration schedule. They use the same molecule but are different products with different FDA labels.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." The New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
2. Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4)." JAMA, 2021. DOI: 10.1001/jama.2021.3224
3. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." The New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2307563
4. Novo Nordisk. "Wegovy (semaglutide) Prescribing Information." novo-pi.com/wegovy.pdf
5. U.S. Food and Drug Administration. "FDA Approves New Drug Treatment for Chronic Weight Management." fda.gov

Done Dose tracks your Wegovy titration schedule, injection sites, side effects, and weight -- all in one place. Download Done Dose to stay consistent with your weekly injections.